SoftBank Group has announced a strategic joint venture with Tempus AI, an AI-driven medical data analysis company. Revealed by SoftBank’s CEO Masayoshi Son, this partnership signifies another major investment in AI by SoftBank, following a $200 million investment in Tempus earlier this year. Tempus, known for its genomic testing and AI-powered treatment recommendations, aims to bring its advanced healthcare services to Japan. The joint venture, set to close in July, involves a $93 million investment from each party. Google has also shown substantial support for Tempus, bolstering its AI capabilities and contributing to its growth. Tempus recently went public on Nasdaq, achieving a market cap of $6 billion and collaborating with top pharmaceutical companies and academic medical centers. This partnership with SoftBank positions Tempus AI as a leader in AI-powered healthcare services, promising significant advancements in medical diagnostics and treatment in Japan.
SoftBank Partners with Tempus AI to Revolutionize Healthcare in Japan
SoftBank and Tempus AI join forces to enhance healthcare in Japan with AI-driven solutions.
1–2 minutes
TOP STORIES
Unauthorized users have gained access to Anthropic’s Mythos, raising security concerns …
Clarifai has deleted millions of photos from OkCupid amid an FTC investigation into data misuse …
Nvidia’s Vera Rubin platform is set to revolutionize AI inference with unmatched performance …
Apple’s leadership transition highlights a strategic focus on silicon for AI innovation …
Apple’s leadership changes signal a strategic shift towards AI and silicon innovation …
Tennessee’s new law restricts AI claims in mental health but may create loopholes …
